ESR1 and neoplasm: First, the favorable prognostic impact of several immune features in the tumor was demonstrated: tumor-infiltrating lymphocytes (TILs) [1,2], immune expression signatures, notably for ER-negative, highly proliferative tumors [3,4,5,6], or expression of PDL1 in triple-negative breast cancer (TNBC) [7].